Post Profile






Response Rate High for Some Patients with Metastatic Melanoma Treated with Vemurafenib

An international team of researchers from the United States and Australia, including researchers at Moffitt Cancer Center, have found that the oral BRAF inhibitor vemurafenib (PLX4032) when tested in a phase II clinical trial offered a high rate of response in patients with previously treated metastatic melanoma and who had the BRAF mutation. More than 50 percent of the patients in the trial had positive, prolonged responses and a median survival of almost 16 months.
read more

share

Related Posts


Researchers Find Potential Solution To Melanoma's Resistance To Vemurafenib

Health : Newswise Medical News

Researchers at Moffitt Cancer Center and colleagues in California have found that the XL888 inhibitor can prevent resistance to the chemotherapy drug vemurafenib, commonly used for treating patients with melanoma.

Plexxikon Announces First Patient Dosed In Phase 3 Trial Of PLX4032 (RG7204) For Metastatic Melanoma

Health : Medical News Today

Plexxikon Inc. announces that enrollment has been initiated and the first patient has been dosed in a pivotal Phase 3 trial of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly targeted drug ...

Response rate high for some patients with metastatic melanoma treated with vemurafenib

Academics / General Science : Science Codex

TAMPA, Fla. (March 16, 2012) – An international team of researchers from the United States and Australia, including researchers at Moffitt Cancer Center in Tampa, Fla., have found that the oral BRAF inhibitor vemurafenib (PLX4032) w...

Vemurafenib Effective For Some Metastatic Melanoma Patients

Health : Medical News Today

Results from a phase II multi-center clinical trial involving 132 patients with previously treated BRAF V600-mutant metastatic melanoma, indicate that vemurafenib (PLX4032) - an oral BRAF inhibitor - offered a high rate of response ...

Vemurafenib Extends Survival To 16 Months For Some Patients With Metastatic Melanoma

Health : Medical News Today

An international team of researchers from the United States and Australia, including researchers at Moffitt Cancer Center in Tampa, Fla., have found that the oral BRAF inhibitor vemurafenib (PLX4032) when tested in a phase II clinic...

Comments



Copyright © 2015 Regator, LLC